Cardiovascular Drug Therapy in the Elderly
... a decreased Vd, and a higher initial plasma concentration.9 In the elderly, there is also a tendency for plasma albumin concentration to be reduced.10 Weak acids, such as salicylates and warfarin, bind extensively to albumin. Decreased binding of drugs such as warfarin to plasma albumin may result i ...
... a decreased Vd, and a higher initial plasma concentration.9 In the elderly, there is also a tendency for plasma albumin concentration to be reduced.10 Weak acids, such as salicylates and warfarin, bind extensively to albumin. Decreased binding of drugs such as warfarin to plasma albumin may result i ...
Newer Pharmacotherapy in Patients Undergoing Percutaneous
... of what constitutes resistance, have been used. Some degree of aspirin resistance may affect 5–45% of the aspirin-taking population.17 The mechanisms of such resistance remain to be fully elucidated but are believed to be a combination of clinical, cellular, genetic, and other factors.18, 19 The opt ...
... of what constitutes resistance, have been used. Some degree of aspirin resistance may affect 5–45% of the aspirin-taking population.17 The mechanisms of such resistance remain to be fully elucidated but are believed to be a combination of clinical, cellular, genetic, and other factors.18, 19 The opt ...
inhibace
... As with other ACE inhibitors, INHIBACE should be used with caution in patients with obstructive cardiac disorders (e.g. mitral stenosis, aortic stenosis, hypertrophic cardiomyopathy), since cardiac output cannot increase to compensate for systemic vasodilation, and there is a risk of severe hypotens ...
... As with other ACE inhibitors, INHIBACE should be used with caution in patients with obstructive cardiac disorders (e.g. mitral stenosis, aortic stenosis, hypertrophic cardiomyopathy), since cardiac output cannot increase to compensate for systemic vasodilation, and there is a risk of severe hypotens ...
Cyclooxygenase inhibition: between the devil and the deep blue sea
... stayed in the study until its completion. Patients were not endoscoped at baseline and, to mimic real life, investigators were not given a protocol for the management of GI complaints. Instead, these were investigated according to standard clinical practice at the physician’s discretion. In addition ...
... stayed in the study until its completion. Patients were not endoscoped at baseline and, to mimic real life, investigators were not given a protocol for the management of GI complaints. Instead, these were investigated according to standard clinical practice at the physician’s discretion. In addition ...
1-Renal excretion of drugs
... Only lipid soluble drugs (non-ionized) undergo passive tubular re-absorption from tubular lumen back into blood (not excreted in the urine, urinary excretion will be low). ...
... Only lipid soluble drugs (non-ionized) undergo passive tubular re-absorption from tubular lumen back into blood (not excreted in the urine, urinary excretion will be low). ...
Understanding and Managing Atrial Fibrillation in Patients
... Patients treated with amiodarone, even at the low doses were at higher risk for thyroid dysfunction and pulmonary toxicity. Dronedarone is mostly excreted in feces, so no initial adjustment of dose necessary. It is less effective than amiodarone and contraindicated in type III/ IV NYHA heart failure ...
... Patients treated with amiodarone, even at the low doses were at higher risk for thyroid dysfunction and pulmonary toxicity. Dronedarone is mostly excreted in feces, so no initial adjustment of dose necessary. It is less effective than amiodarone and contraindicated in type III/ IV NYHA heart failure ...
Acetaminophen and Hepatotoxicity
... • A small fraction of acetaminophen is metabolized by the microsomal cytochrome P450 enzymes; The CYP 2E1 enzyme produces a toxic metabolite of acetaminophen known as N-acetyl-p-benzo-quinone (NAPQI) • At normal doses, only trace amounts of NAPQI are formed, which is bound to and inactivated by glut ...
... • A small fraction of acetaminophen is metabolized by the microsomal cytochrome P450 enzymes; The CYP 2E1 enzyme produces a toxic metabolite of acetaminophen known as N-acetyl-p-benzo-quinone (NAPQI) • At normal doses, only trace amounts of NAPQI are formed, which is bound to and inactivated by glut ...
PROSOGAN® INJECTION Lansoprazole
... glucose injection and administered slowly by intravenous injection twice a day. 1. As PROSOGAN ® Injection 30 mg was shown to have high hemostatic effect based on the data up to 3 days after starting treatment, once the patient is able to take medications orally, therapy should be switched to an ora ...
... glucose injection and administered slowly by intravenous injection twice a day. 1. As PROSOGAN ® Injection 30 mg was shown to have high hemostatic effect based on the data up to 3 days after starting treatment, once the patient is able to take medications orally, therapy should be switched to an ora ...
Point of care coagulation testing and tr
... (clot strengthening). The MA reflects the ultimate strength of the clot which depends on the number and function of platelets and their interaction with fibrin. The MA is the parameter most frequently measured because it correlates with platelet dysfunction in cardiac surgery. The MA is used as a ma ...
... (clot strengthening). The MA reflects the ultimate strength of the clot which depends on the number and function of platelets and their interaction with fibrin. The MA is the parameter most frequently measured because it correlates with platelet dysfunction in cardiac surgery. The MA is used as a ma ...
Avalide (irbesartan hydrochlorothiazide)
... risk of teratogenicity following exposure to ACE inhibitors (another class of therapeutic products interfering with the RAAS) during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with AR ...
... risk of teratogenicity following exposure to ACE inhibitors (another class of therapeutic products interfering with the RAAS) during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with AR ...
Prescribing Information - Novartis Pharmaceuticals Corporation
... patients with severe congestive heart failure), treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria, progressive azotemia and, rarely, acute renal failure and death. Closely monitor serum creatinine, and down-titrate or interrupt ENTRESTO in patients ...
... patients with severe congestive heart failure), treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria, progressive azotemia and, rarely, acute renal failure and death. Closely monitor serum creatinine, and down-titrate or interrupt ENTRESTO in patients ...
الشريحة 1
... site of the COX-2 enzyme much more effectively than that of COX-1. COX-2 inhibitors have analgesic, antipyretic, and anti-inflammatory effects similar to those of nonselective NSAIDs but with an approximate halving of gastrointestinal adverse effects. Likewise, COX-2 inhibitors at usual doses have b ...
... site of the COX-2 enzyme much more effectively than that of COX-1. COX-2 inhibitors have analgesic, antipyretic, and anti-inflammatory effects similar to those of nonselective NSAIDs but with an approximate halving of gastrointestinal adverse effects. Likewise, COX-2 inhibitors at usual doses have b ...
Hepatitis C therapy-the future looks bright
... ribavirin and interferon-α have remained the only available medicines for treating hepatitis C sufferers. Given that this combination therapy is partially effective at best and is associated with severe side-effects, there is an unmet need for new molecular entities which inhibit HCV replication. By ...
... ribavirin and interferon-α have remained the only available medicines for treating hepatitis C sufferers. Given that this combination therapy is partially effective at best and is associated with severe side-effects, there is an unmet need for new molecular entities which inhibit HCV replication. By ...
Equianalgesic Dosing of Opioids for Pain Management
... Most of the above oral opioids are available as generics. Exceptions (prices are AWP [U.S.]) include: Kadian ($6.63/30 mg cap), Avinza ($5.45/ 30 mg cap), Opana ($6.53/10 mg tab), Opana ER ($4.35/10 mg tab), OxyContin ($2.43/10 mg tab), Embeda ($4.98/20 mg cap), and Exalgo ($8.99/ 8 mg). As a compar ...
... Most of the above oral opioids are available as generics. Exceptions (prices are AWP [U.S.]) include: Kadian ($6.63/30 mg cap), Avinza ($5.45/ 30 mg cap), Opana ($6.53/10 mg tab), Opana ER ($4.35/10 mg tab), OxyContin ($2.43/10 mg tab), Embeda ($4.98/20 mg cap), and Exalgo ($8.99/ 8 mg). As a compar ...
Therapeutic Drug Monitoring
... Digoxin therapy should be monitored by clinical effect rather than serum levels. Digoxin serum levels are meaningless ...
... Digoxin therapy should be monitored by clinical effect rather than serum levels. Digoxin serum levels are meaningless ...
Running head: PERSONAL DRUGS PERSONAL DRUGS Personal
... dosage adjustment may be required. Avoid use with infectious mononucleosis (high risk for developing rash). Drug-drug interactions: Avoid concomitant use with BCG. Allopurinol may increase effects. ...
... dosage adjustment may be required. Avoid use with infectious mononucleosis (high risk for developing rash). Drug-drug interactions: Avoid concomitant use with BCG. Allopurinol may increase effects. ...
Guidelines for use of Digoxin (Lanoxin )
... 3. IM injection should be discouraged, as absorption is only 80% compared to IV; local irritation, muscle damage, and necrosis may also occur 4. ECG & Lead II strips must be read prior to Digitalizing doses; *Cardiology must be consulted prior to beginning therapy. 5. Electrolytes and total fluids m ...
... 3. IM injection should be discouraged, as absorption is only 80% compared to IV; local irritation, muscle damage, and necrosis may also occur 4. ECG & Lead II strips must be read prior to Digitalizing doses; *Cardiology must be consulted prior to beginning therapy. 5. Electrolytes and total fluids m ...
Glycopyrronium (as bromide) - Therapeutic Goods Administration
... Renal elimination of parent drug accounts for about 60 to 70% of total clearance of systemically available glycopyrronium whereas non-renal clearance processes account for about 30 to 40%. Biliary clearance contributes to the non-renal clearance, but the majority of non-renal clearance is thought to ...
... Renal elimination of parent drug accounts for about 60 to 70% of total clearance of systemically available glycopyrronium whereas non-renal clearance processes account for about 30 to 40%. Biliary clearance contributes to the non-renal clearance, but the majority of non-renal clearance is thought to ...
PGX Test Monographs
... CYP286 enzyme activity defines a normal or an abnormal (intermediate or poor) metabolizer status for a given individual. Several variant alleles have been identified and result in different CYP286 isoforms that functionally are fully active, partially active, inactive, or have increased activity. Th ...
... CYP286 enzyme activity defines a normal or an abnormal (intermediate or poor) metabolizer status for a given individual. Several variant alleles have been identified and result in different CYP286 isoforms that functionally are fully active, partially active, inactive, or have increased activity. Th ...
Platelet glycoprotein IIb/IIIa receptor blockade in coronary
... Cleveland, Ohio and Durham, North Carolina New strategies for profound inhibition of platelet activity at the injured coronary plaque focus on blockade of the platelet surface membrane glycoprotein IIb/IIIa receptor, which binds circulating fibrinogen or von Willebrand factor and crosslinks platelet ...
... Cleveland, Ohio and Durham, North Carolina New strategies for profound inhibition of platelet activity at the injured coronary plaque focus on blockade of the platelet surface membrane glycoprotein IIb/IIIa receptor, which binds circulating fibrinogen or von Willebrand factor and crosslinks platelet ...
Ketorolac Tromethamine
... also contraindicated in a history of peptic ulcer or gastro-intestinal bleeding, moderate or severe renal impairment (serum creatinine> 160 micromol/l), a history of asthma and haemorrhagic diatheses including coagulation disorders. Ket (Ketorolac Tromethamine) is also contraindicated for children u ...
... also contraindicated in a history of peptic ulcer or gastro-intestinal bleeding, moderate or severe renal impairment (serum creatinine> 160 micromol/l), a history of asthma and haemorrhagic diatheses including coagulation disorders. Ket (Ketorolac Tromethamine) is also contraindicated for children u ...
Factors Associated With Major Bleeding Events
... The principal safety endpoint was defined as major bleeding or nonmajor clinically relevant bleeding. Major bleeding was defined as that which was clinically overt and associated with any of the following: fatal outcome; involvement of a critical anatomic site (intracranial, spinal, ocular, pericardia ...
... The principal safety endpoint was defined as major bleeding or nonmajor clinically relevant bleeding. Major bleeding was defined as that which was clinically overt and associated with any of the following: fatal outcome; involvement of a critical anatomic site (intracranial, spinal, ocular, pericardia ...
Factors Associated With Major Bleeding Events
... The principal safety endpoint was defined as major bleeding or nonmajor clinically relevant bleeding. Major bleeding was defined as that which was clinically overt and associated with any of the following: fatal outcome; involvement of a critical anatomic site (intracranial, spinal, ocular, pericardia ...
... The principal safety endpoint was defined as major bleeding or nonmajor clinically relevant bleeding. Major bleeding was defined as that which was clinically overt and associated with any of the following: fatal outcome; involvement of a critical anatomic site (intracranial, spinal, ocular, pericardia ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.